Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | MLNR | O43193 | 3/20 | 0.41 |
| ▸ | MELK | Q14680 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181956 | 0.84 | MLNR (0.46) | SYKAURKBINCENPHTR2BMLNR | |
| SCHEMBL5660251 | 0.83 | SYK (0.48) | SYKAURKBINCENPMLNRCYP2D6 | |
| SCHEMBL5660536 | 0.80 | HRH3 (0.66) | CYP2D6HRH3PRMT5WDR77 | |
| SCHEMBL5661913 | 0.78 | GPR119 (0.47) | HRH3NPC1MAPTPRMT5WDR77 | |
| SCHEMBL5662183 | 0.76 | MLNR (0.43) | SYKAURKBINCENPHTR2BMLNR | |
| SCHEMBL3077653 | 0.76 | HRH3 (0.67) | SYKAURKBINCENPMLNRCYP2D6 | |
| SCHEMBL5172384 | 0.74 | MLNR (0.50) | SYKAURKBINCENPHTR2BMLNR | |
| SCHEMBL5168814 | 0.72 | HRH3 (0.47) | SYKAURKBINCENPMLNRMELK | |
| SCHEMBL5660505 | 0.70 | MLNR (0.40) | SYKAURKBINCENPMLNR | |
| SCHEMBL5664229 | 0.70 | CYP11B1 (0.42) | SYKAURKBINCENPHTR2BMLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208005-A1 | TETRAHYDROBENZAZEPINES AS ANTAGONISTS AND/OR REVERSE AGONISTS OF THE HISTAMINE H3 RECEPTOR | HRH3, HRH4, HRH1 | SYK 4267/4885AURKB 1120/4885INCENP 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.